President MessageNeptune Technologies has made significant progress solidifying and positioning the Company to meet the challenges of its next growth and expansion phase. Significant achievements have been made with the objective to continue its transition from the dietary supplements segment to functional and medical foods and into pharmaceuticals. Neptune is currently negotiating strategic alliances for raw material supply and high scale production for the nutraceutical and pharmaceutical applications with major suppliers and multinational industrial manufacturing partners. Neptune is progressing with plans to increase plant capacity and continue to improve productivity. The Company is continuously researching, developing and testing new products and formulations for nutraceutical applications within the OPA3 family with health benefits for cardiovascular, neurological and inflammatory diseases. This effort will result in entering new dietary supplement distributor agreements, advancing the Nestlé and Yoplait functional food products through its development and testing phases, and in partnering with other multinational food companies exploiting its three therapeutic applications within the four food categories (dairy, cereals/bars, juice/beverages, confectionary). Neptune has advanced its internal pharmaceutical operations which led to the set up of Acasti Pharma for cardiovascular applications and NeuroBioPharm for neurological applications with the objective to further advance the pharmaceutical programs including an over-the-counter drug, a prescription medical food and a prescription drug and to continue to pursue strategic alliances with pharmaceutical companies. Neptune continues to focus on building the fundamentals of the Company which leads Neptune toward its primary objective of increasing Company value and shareholder wealth. Henri Harland, President & Chief Executive Officer |